Abstract
Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Keywords: Anxiety, model, anxiolytic, drug development, humans
Current Neuropharmacology
Title: Modelling Anxiety in Humans for Drug Development
Volume: 5 Issue: 1
Author(s): Martin Siepmann and Peter Joraschky
Affiliation:
Keywords: Anxiety, model, anxiolytic, drug development, humans
Abstract: Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Export Options
About this article
Cite this article as:
Siepmann Martin and Joraschky Peter, Modelling Anxiety in Humans for Drug Development, Current Neuropharmacology 2007; 5 (1) . https://dx.doi.org/10.2174/157015907780077114
DOI https://dx.doi.org/10.2174/157015907780077114 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia
Current Pharmaceutical Design Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Current Neuropharmacology Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Stress and Brain Atrophy
CNS & Neurological Disorders - Drug Targets Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Histamine H3-Receptor Inverse Agonists as Novel Antipsychotics
Central Nervous System Agents in Medicinal Chemistry Visceral Pain: Spinal Afferents, Enteric Mast Cells, Enteric Nervous System and Stress
Current Pharmaceutical Design Primate-Accelerated Evolutionary Genes: Novel Routes to Drug Discovery in Psychiatric Disorders
Current Medicinal Chemistry The Effects of Healthy Ageing on Cerebral Blood Flow Responses to Cognitive Testing
Current Aging Science Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction
Current Drug Targets Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Bedside Balance Testing in Elderly People
Current Aging Science Substance-Induced Psychoses: A Critical Review of the Literature
Current Drug Abuse Reviews Programmed Symptoms: Disparate Effects United by Purpose
Current Rheumatology Reviews PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry